nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—melanoma	0.226	0.529	CbGaD
Naproxen—ALB—melanoma	0.201	0.471	CbGaD
Naproxen—ALB—Vemurafenib—melanoma	0.0981	0.355	CbGbCtD
Naproxen—CYP1A2—Carmustine—melanoma	0.0743	0.269	CbGbCtD
Naproxen—CYP1A2—Vemurafenib—melanoma	0.0587	0.213	CbGbCtD
Naproxen—CYP1A2—Dacarbazine—melanoma	0.045	0.163	CbGbCtD
Naproxen—Indomethacin—GLO1—melanoma	0.00169	0.205	CrCbGaD
Naproxen—Ketoprofen—CXCR1—melanoma	0.00159	0.193	CrCbGaD
Naproxen—Indomethacin—CXCL8—melanoma	0.0005	0.0609	CrCbGaD
Naproxen—Ibuprofen—BCL2—melanoma	0.000491	0.0598	CrCbGaD
Naproxen—Ketoprofen—CXCL8—melanoma	0.0004	0.0487	CrCbGaD
Naproxen—Ibuprofen—CXCL8—melanoma	0.000394	0.0479	CrCbGaD
Naproxen—Nabumetone—PTGS2—melanoma	0.000389	0.0474	CrCbGaD
Naproxen—Carprofen—PTGS2—melanoma	0.000371	0.0452	CrCbGaD
Naproxen—Indomethacin—PPARG—melanoma	0.000346	0.0421	CrCbGaD
Naproxen—Immune system disorder—Temozolomide—melanoma	0.000279	0.00148	CcSEcCtD
Naproxen—Mediastinal disorder—Temozolomide—melanoma	0.000279	0.00148	CcSEcCtD
Naproxen—Malnutrition—Carmustine—melanoma	0.000279	0.00148	CcSEcCtD
Naproxen—Erythema—Carmustine—melanoma	0.000279	0.00148	CcSEcCtD
Naproxen—Cough—Bleomycin—melanoma	0.000278	0.00148	CcSEcCtD
Naproxen—Chills—Temozolomide—melanoma	0.000277	0.00147	CcSEcCtD
Naproxen—Dehydration—Docetaxel—melanoma	0.000276	0.00147	CcSEcCtD
Naproxen—Ill-defined disorder—Dactinomycin—melanoma	0.000276	0.00146	CcSEcCtD
Naproxen—Anaemia—Dactinomycin—melanoma	0.000275	0.00146	CcSEcCtD
Naproxen—Liver function test abnormal—Docetaxel—melanoma	0.000274	0.00146	CcSEcCtD
Naproxen—Vomiting—Vemurafenib—melanoma	0.000273	0.00145	CcSEcCtD
Naproxen—Alopecia—Temozolomide—melanoma	0.000273	0.00145	CcSEcCtD
Naproxen—Dry skin—Docetaxel—melanoma	0.000272	0.00144	CcSEcCtD
Naproxen—Ibuprofen—PPARG—melanoma	0.000272	0.0331	CrCbGaD
Naproxen—Myalgia—Bleomycin—melanoma	0.000272	0.00144	CcSEcCtD
Naproxen—Chest pain—Bleomycin—melanoma	0.000272	0.00144	CcSEcCtD
Naproxen—Abdominal pain upper—Docetaxel—melanoma	0.000271	0.00144	CcSEcCtD
Naproxen—Rash—Vemurafenib—melanoma	0.000271	0.00144	CcSEcCtD
Naproxen—Mental disorder—Temozolomide—melanoma	0.000271	0.00144	CcSEcCtD
Naproxen—Dermatitis—Vemurafenib—melanoma	0.000271	0.00144	CcSEcCtD
Naproxen—Headache—Vemurafenib—melanoma	0.000269	0.00143	CcSEcCtD
Naproxen—Malnutrition—Temozolomide—melanoma	0.000269	0.00143	CcSEcCtD
Naproxen—Erythema—Temozolomide—melanoma	0.000269	0.00143	CcSEcCtD
Naproxen—Breast disorder—Docetaxel—melanoma	0.000269	0.00142	CcSEcCtD
Naproxen—Discomfort—Bleomycin—melanoma	0.000268	0.00142	CcSEcCtD
Naproxen—Malaise—Dactinomycin—melanoma	0.000268	0.00142	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000268	0.00142	CcSEcCtD
Naproxen—Cramp muscle—Docetaxel—melanoma	0.000268	0.00142	CcSEcCtD
Naproxen—Leukopenia—Dactinomycin—melanoma	0.000266	0.00141	CcSEcCtD
Naproxen—Confusional state—Bleomycin—melanoma	0.000263	0.00139	CcSEcCtD
Naproxen—Vision blurred—Carmustine—melanoma	0.000262	0.00139	CcSEcCtD
Naproxen—Tremor—Carmustine—melanoma	0.000261	0.00138	CcSEcCtD
Naproxen—Oedema—Bleomycin—melanoma	0.00026	0.00138	CcSEcCtD
Naproxen—Anaphylactic shock—Bleomycin—melanoma	0.00026	0.00138	CcSEcCtD
Naproxen—Infection—Bleomycin—melanoma	0.000259	0.00137	CcSEcCtD
Naproxen—Anaemia—Carmustine—melanoma	0.000257	0.00137	CcSEcCtD
Naproxen—Dysphagia—Docetaxel—melanoma	0.000257	0.00136	CcSEcCtD
Naproxen—Nausea—Vemurafenib—melanoma	0.000255	0.00135	CcSEcCtD
Naproxen—Thrombocytopenia—Bleomycin—melanoma	0.000255	0.00135	CcSEcCtD
Naproxen—Vision blurred—Temozolomide—melanoma	0.000254	0.00135	CcSEcCtD
Naproxen—Myalgia—Dactinomycin—melanoma	0.000253	0.00134	CcSEcCtD
Naproxen—Tremor—Temozolomide—melanoma	0.000252	0.00134	CcSEcCtD
Naproxen—Discomfort—Dactinomycin—melanoma	0.00025	0.00133	CcSEcCtD
Naproxen—Angina pectoris—Docetaxel—melanoma	0.00025	0.00133	CcSEcCtD
Naproxen—Ill-defined disorder—Temozolomide—melanoma	0.00025	0.00132	CcSEcCtD
Naproxen—Leukopenia—Carmustine—melanoma	0.000249	0.00132	CcSEcCtD
Naproxen—Anaemia—Temozolomide—melanoma	0.000249	0.00132	CcSEcCtD
Naproxen—Anorexia—Bleomycin—melanoma	0.000248	0.00132	CcSEcCtD
Naproxen—Angioedema—Temozolomide—melanoma	0.000246	0.0013	CcSEcCtD
Naproxen—Pancytopenia—Docetaxel—melanoma	0.000244	0.00129	CcSEcCtD
Naproxen—Hypotension—Bleomycin—melanoma	0.000243	0.00129	CcSEcCtD
Naproxen—Oedema—Dactinomycin—melanoma	0.000243	0.00129	CcSEcCtD
Naproxen—Malaise—Temozolomide—melanoma	0.000243	0.00129	CcSEcCtD
Naproxen—Vertigo—Temozolomide—melanoma	0.000242	0.00128	CcSEcCtD
Naproxen—Convulsion—Carmustine—melanoma	0.000241	0.00128	CcSEcCtD
Naproxen—Infection—Dactinomycin—melanoma	0.000241	0.00128	CcSEcCtD
Naproxen—Leukopenia—Temozolomide—melanoma	0.000241	0.00128	CcSEcCtD
Naproxen—Hypertension—Carmustine—melanoma	0.00024	0.00128	CcSEcCtD
Naproxen—Palpitations—Temozolomide—melanoma	0.000238	0.00126	CcSEcCtD
Naproxen—Thrombocytopenia—Dactinomycin—melanoma	0.000238	0.00126	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Bleomycin—melanoma	0.000237	0.00126	CcSEcCtD
Naproxen—Myalgia—Carmustine—melanoma	0.000237	0.00126	CcSEcCtD
Naproxen—Chest pain—Carmustine—melanoma	0.000237	0.00126	CcSEcCtD
Naproxen—Anxiety—Carmustine—melanoma	0.000236	0.00125	CcSEcCtD
Naproxen—Cough—Temozolomide—melanoma	0.000235	0.00125	CcSEcCtD
Naproxen—Paraesthesia—Bleomycin—melanoma	0.000234	0.00124	CcSEcCtD
Naproxen—Convulsion—Temozolomide—melanoma	0.000233	0.00124	CcSEcCtD
Naproxen—Weight decreased—Docetaxel—melanoma	0.000232	0.00123	CcSEcCtD
Naproxen—Hypertension—Temozolomide—melanoma	0.000232	0.00123	CcSEcCtD
Naproxen—Dyspnoea—Bleomycin—melanoma	0.000232	0.00123	CcSEcCtD
Naproxen—Anorexia—Dactinomycin—melanoma	0.000231	0.00123	CcSEcCtD
Naproxen—Pneumonia—Docetaxel—melanoma	0.00023	0.00122	CcSEcCtD
Naproxen—Suprofen—PTGS2—melanoma	0.000229	0.0279	CrCbGaD
Naproxen—Confusional state—Carmustine—melanoma	0.000229	0.00122	CcSEcCtD
Naproxen—Arthralgia—Temozolomide—melanoma	0.000229	0.00122	CcSEcCtD
Naproxen—Myalgia—Temozolomide—melanoma	0.000229	0.00122	CcSEcCtD
Naproxen—Anxiety—Temozolomide—melanoma	0.000228	0.00121	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000228	0.00121	CcSEcCtD
Naproxen—Oedema—Carmustine—melanoma	0.000227	0.00121	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000227	0.0012	CcSEcCtD
Naproxen—Discomfort—Temozolomide—melanoma	0.000226	0.0012	CcSEcCtD
Naproxen—Decreased appetite—Bleomycin—melanoma	0.000226	0.0012	CcSEcCtD
Naproxen—Infection—Carmustine—melanoma	0.000226	0.0012	CcSEcCtD
Naproxen—Acute coronary syndrome—Docetaxel—melanoma	0.000226	0.0012	CcSEcCtD
Naproxen—Renal failure—Docetaxel—melanoma	0.000225	0.00119	CcSEcCtD
Naproxen—Myocardial infarction—Docetaxel—melanoma	0.000225	0.00119	CcSEcCtD
Naproxen—Neuropathy peripheral—Docetaxel—melanoma	0.000225	0.00119	CcSEcCtD
Naproxen—Dry mouth—Temozolomide—melanoma	0.000224	0.00119	CcSEcCtD
Naproxen—Stomatitis—Docetaxel—melanoma	0.000223	0.00118	CcSEcCtD
Naproxen—Jaundice—Docetaxel—melanoma	0.000223	0.00118	CcSEcCtD
Naproxen—Pain—Bleomycin—melanoma	0.000223	0.00118	CcSEcCtD
Naproxen—Conjunctivitis—Docetaxel—melanoma	0.000223	0.00118	CcSEcCtD
Naproxen—Thrombocytopenia—Carmustine—melanoma	0.000223	0.00118	CcSEcCtD
Naproxen—Tachycardia—Carmustine—melanoma	0.000222	0.00118	CcSEcCtD
Naproxen—Confusional state—Temozolomide—melanoma	0.000221	0.00117	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000221	0.00117	CcSEcCtD
Naproxen—Oedema—Temozolomide—melanoma	0.00022	0.00116	CcSEcCtD
Naproxen—Anaphylactic shock—Temozolomide—melanoma	0.00022	0.00116	CcSEcCtD
Naproxen—Infection—Temozolomide—melanoma	0.000218	0.00116	CcSEcCtD
Naproxen—Anorexia—Carmustine—melanoma	0.000217	0.00115	CcSEcCtD
Naproxen—Hepatobiliary disease—Docetaxel—melanoma	0.000217	0.00115	CcSEcCtD
Naproxen—Epistaxis—Docetaxel—melanoma	0.000216	0.00115	CcSEcCtD
Naproxen—Nervous system disorder—Temozolomide—melanoma	0.000215	0.00114	CcSEcCtD
Naproxen—Thrombocytopenia—Temozolomide—melanoma	0.000215	0.00114	CcSEcCtD
Naproxen—Feeling abnormal—Bleomycin—melanoma	0.000215	0.00114	CcSEcCtD
Naproxen—Agranulocytosis—Docetaxel—melanoma	0.000214	0.00113	CcSEcCtD
Naproxen—Skin disorder—Temozolomide—melanoma	0.000213	0.00113	CcSEcCtD
Naproxen—Hypotension—Carmustine—melanoma	0.000212	0.00113	CcSEcCtD
Naproxen—Hyperhidrosis—Temozolomide—melanoma	0.000212	0.00113	CcSEcCtD
Naproxen—Decreased appetite—Dactinomycin—melanoma	0.000211	0.00112	CcSEcCtD
Naproxen—Fatigue—Dactinomycin—melanoma	0.000209	0.00111	CcSEcCtD
Naproxen—Anorexia—Temozolomide—melanoma	0.000209	0.00111	CcSEcCtD
Naproxen—Pain—Dactinomycin—melanoma	0.000208	0.0011	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Carmustine—melanoma	0.000207	0.0011	CcSEcCtD
Naproxen—Urticaria—Bleomycin—melanoma	0.000207	0.0011	CcSEcCtD
Naproxen—Haemoglobin—Docetaxel—melanoma	0.000207	0.0011	CcSEcCtD
Naproxen—Rhinitis—Docetaxel—melanoma	0.000206	0.00109	CcSEcCtD
Naproxen—Body temperature increased—Bleomycin—melanoma	0.000206	0.00109	CcSEcCtD
Naproxen—Haemorrhage—Docetaxel—melanoma	0.000206	0.00109	CcSEcCtD
Naproxen—Hepatitis—Docetaxel—melanoma	0.000206	0.00109	CcSEcCtD
Naproxen—Insomnia—Carmustine—melanoma	0.000206	0.00109	CcSEcCtD
Naproxen—Paraesthesia—Carmustine—melanoma	0.000204	0.00108	CcSEcCtD
Naproxen—Pharyngitis—Docetaxel—melanoma	0.000204	0.00108	CcSEcCtD
Naproxen—Urinary tract disorder—Docetaxel—melanoma	0.000203	0.00108	CcSEcCtD
Naproxen—Dyspnoea—Carmustine—melanoma	0.000203	0.00107	CcSEcCtD
Naproxen—Oedema peripheral—Docetaxel—melanoma	0.000203	0.00107	CcSEcCtD
Naproxen—Somnolence—Carmustine—melanoma	0.000202	0.00107	CcSEcCtD
Naproxen—Connective tissue disorder—Docetaxel—melanoma	0.000202	0.00107	CcSEcCtD
Naproxen—Urethral disorder—Docetaxel—melanoma	0.000202	0.00107	CcSEcCtD
Naproxen—Feeling abnormal—Dactinomycin—melanoma	0.0002	0.00106	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Temozolomide—melanoma	0.0002	0.00106	CcSEcCtD
Naproxen—Insomnia—Temozolomide—melanoma	0.000199	0.00105	CcSEcCtD
Naproxen—Gastrointestinal pain—Dactinomycin—melanoma	0.000199	0.00105	CcSEcCtD
Naproxen—Visual impairment—Docetaxel—melanoma	0.000198	0.00105	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—melanoma	0.000198	0.0241	CrCbGaD
Naproxen—Decreased appetite—Carmustine—melanoma	0.000198	0.00105	CcSEcCtD
Naproxen—Paraesthesia—Temozolomide—melanoma	0.000197	0.00105	CcSEcCtD
Naproxen—Gastrointestinal disorder—Carmustine—melanoma	0.000196	0.00104	CcSEcCtD
Naproxen—Dyspnoea—Temozolomide—melanoma	0.000196	0.00104	CcSEcCtD
Naproxen—Somnolence—Temozolomide—melanoma	0.000195	0.00104	CcSEcCtD
Naproxen—Erythema multiforme—Docetaxel—melanoma	0.000194	0.00103	CcSEcCtD
Naproxen—Constipation—Carmustine—melanoma	0.000194	0.00103	CcSEcCtD
Naproxen—Pain—Carmustine—melanoma	0.000194	0.00103	CcSEcCtD
Naproxen—Dyspepsia—Temozolomide—melanoma	0.000193	0.00103	CcSEcCtD
Naproxen—Eye disorder—Docetaxel—melanoma	0.000192	0.00102	CcSEcCtD
Naproxen—Body temperature increased—Dactinomycin—melanoma	0.000192	0.00102	CcSEcCtD
Naproxen—Abdominal pain—Dactinomycin—melanoma	0.000192	0.00102	CcSEcCtD
Naproxen—Hypersensitivity—Bleomycin—melanoma	0.000192	0.00102	CcSEcCtD
Naproxen—Decreased appetite—Temozolomide—melanoma	0.000191	0.00101	CcSEcCtD
Naproxen—Cardiac disorder—Docetaxel—melanoma	0.000191	0.00101	CcSEcCtD
Naproxen—Gastrointestinal disorder—Temozolomide—melanoma	0.00019	0.00101	CcSEcCtD
Naproxen—Fatigue—Temozolomide—melanoma	0.000189	0.001	CcSEcCtD
Naproxen—Constipation—Temozolomide—melanoma	0.000188	0.000996	CcSEcCtD
Naproxen—Pain—Temozolomide—melanoma	0.000188	0.000996	CcSEcCtD
Naproxen—Feeling abnormal—Carmustine—melanoma	0.000187	0.000993	CcSEcCtD
Naproxen—Asthenia—Bleomycin—melanoma	0.000187	0.000991	CcSEcCtD
Naproxen—Angiopathy—Docetaxel—melanoma	0.000187	0.000989	CcSEcCtD
Naproxen—Gastrointestinal pain—Carmustine—melanoma	0.000186	0.000986	CcSEcCtD
Naproxen—Immune system disorder—Docetaxel—melanoma	0.000186	0.000985	CcSEcCtD
Naproxen—Mediastinal disorder—Docetaxel—melanoma	0.000185	0.000983	CcSEcCtD
Naproxen—Chills—Docetaxel—melanoma	0.000184	0.000978	CcSEcCtD
Naproxen—Pruritus—Bleomycin—melanoma	0.000184	0.000977	CcSEcCtD
Naproxen—Arrhythmia—Docetaxel—melanoma	0.000184	0.000974	CcSEcCtD
Naproxen—Alopecia—Docetaxel—melanoma	0.000182	0.000963	CcSEcCtD
Naproxen—Feeling abnormal—Temozolomide—melanoma	0.000181	0.00096	CcSEcCtD
Naproxen—Mental disorder—Docetaxel—melanoma	0.00018	0.000955	CcSEcCtD
Naproxen—Abdominal pain—Carmustine—melanoma	0.00018	0.000953	CcSEcCtD
Naproxen—Body temperature increased—Carmustine—melanoma	0.00018	0.000953	CcSEcCtD
Naproxen—Gastrointestinal pain—Temozolomide—melanoma	0.00018	0.000952	CcSEcCtD
Naproxen—Malnutrition—Docetaxel—melanoma	0.000179	0.000949	CcSEcCtD
Naproxen—Erythema—Docetaxel—melanoma	0.000179	0.000949	CcSEcCtD
Naproxen—Hypersensitivity—Dactinomycin—melanoma	0.000179	0.000949	CcSEcCtD
Naproxen—Fenoprofen—ALB—melanoma	0.000176	0.0214	CrCbGaD
Naproxen—Urticaria—Temozolomide—melanoma	0.000175	0.000925	CcSEcCtD
Naproxen—Asthenia—Dactinomycin—melanoma	0.000174	0.000924	CcSEcCtD
Naproxen—Body temperature increased—Temozolomide—melanoma	0.000174	0.000921	CcSEcCtD
Naproxen—Abdominal pain—Temozolomide—melanoma	0.000174	0.000921	CcSEcCtD
Naproxen—Muscle spasms—Docetaxel—melanoma	0.000172	0.000913	CcSEcCtD
Naproxen—Hypersensitivity—Carmustine—melanoma	0.000167	0.000888	CcSEcCtD
Naproxen—Diarrhoea—Dactinomycin—melanoma	0.000166	0.000881	CcSEcCtD
Naproxen—Vomiting—Bleomycin—melanoma	0.000166	0.000878	CcSEcCtD
Naproxen—Anaemia—Docetaxel—melanoma	0.000165	0.000877	CcSEcCtD
Naproxen—Rash—Bleomycin—melanoma	0.000164	0.000871	CcSEcCtD
Naproxen—Dermatitis—Bleomycin—melanoma	0.000164	0.00087	CcSEcCtD
Naproxen—Asthenia—Carmustine—melanoma	0.000163	0.000865	CcSEcCtD
Naproxen—Hypersensitivity—Temozolomide—melanoma	0.000162	0.000858	CcSEcCtD
Naproxen—Syncope—Docetaxel—melanoma	0.000161	0.000851	CcSEcCtD
Naproxen—Leukopenia—Docetaxel—melanoma	0.00016	0.00085	CcSEcCtD
Naproxen—Palpitations—Docetaxel—melanoma	0.000158	0.000839	CcSEcCtD
Naproxen—Asthenia—Temozolomide—melanoma	0.000158	0.000836	CcSEcCtD
Naproxen—Loss of consciousness—Docetaxel—melanoma	0.000157	0.000834	CcSEcCtD
Naproxen—Cough—Docetaxel—melanoma	0.000156	0.000828	CcSEcCtD
Naproxen—Diarrhoea—Carmustine—melanoma	0.000156	0.000825	CcSEcCtD
Naproxen—Pruritus—Temozolomide—melanoma	0.000155	0.000824	CcSEcCtD
Naproxen—Convulsion—Docetaxel—melanoma	0.000155	0.000822	CcSEcCtD
Naproxen—Nausea—Bleomycin—melanoma	0.000155	0.00082	CcSEcCtD
Naproxen—Hypertension—Docetaxel—melanoma	0.000155	0.000819	CcSEcCtD
Naproxen—Vomiting—Dactinomycin—melanoma	0.000154	0.000819	CcSEcCtD
Naproxen—Rash—Dactinomycin—melanoma	0.000153	0.000812	CcSEcCtD
Naproxen—Myalgia—Docetaxel—melanoma	0.000152	0.000808	CcSEcCtD
Naproxen—Chest pain—Docetaxel—melanoma	0.000152	0.000808	CcSEcCtD
Naproxen—Arthralgia—Docetaxel—melanoma	0.000152	0.000808	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000151	0.000802	CcSEcCtD
Naproxen—Dizziness—Carmustine—melanoma	0.00015	0.000797	CcSEcCtD
Naproxen—Diarrhoea—Temozolomide—melanoma	0.00015	0.000797	CcSEcCtD
Naproxen—Dry mouth—Docetaxel—melanoma	0.000149	0.00079	CcSEcCtD
Naproxen—Confusional state—Docetaxel—melanoma	0.000147	0.000781	CcSEcCtD
Naproxen—Oedema—Docetaxel—melanoma	0.000146	0.000775	CcSEcCtD
Naproxen—Anaphylactic shock—Docetaxel—melanoma	0.000146	0.000775	CcSEcCtD
Naproxen—Indomethacin—PTGS2—melanoma	0.000146	0.0178	CrCbGaD
Naproxen—Dizziness—Temozolomide—melanoma	0.000145	0.00077	CcSEcCtD
Naproxen—Infection—Docetaxel—melanoma	0.000145	0.00077	CcSEcCtD
Naproxen—Vomiting—Carmustine—melanoma	0.000145	0.000766	CcSEcCtD
Naproxen—Nausea—Dactinomycin—melanoma	0.000144	0.000765	CcSEcCtD
Naproxen—Shock—Docetaxel—melanoma	0.000144	0.000762	CcSEcCtD
Naproxen—Rash—Carmustine—melanoma	0.000143	0.00076	CcSEcCtD
Naproxen—Nervous system disorder—Docetaxel—melanoma	0.000143	0.00076	CcSEcCtD
Naproxen—Dermatitis—Carmustine—melanoma	0.000143	0.000759	CcSEcCtD
Naproxen—Thrombocytopenia—Docetaxel—melanoma	0.000143	0.000758	CcSEcCtD
Naproxen—Tachycardia—Docetaxel—melanoma	0.000143	0.000756	CcSEcCtD
Naproxen—Headache—Carmustine—melanoma	0.000142	0.000755	CcSEcCtD
Naproxen—Skin disorder—Docetaxel—melanoma	0.000142	0.000752	CcSEcCtD
Naproxen—Vomiting—Temozolomide—melanoma	0.00014	0.000741	CcSEcCtD
Naproxen—Anorexia—Docetaxel—melanoma	0.000139	0.000738	CcSEcCtD
Naproxen—Rash—Temozolomide—melanoma	0.000138	0.000734	CcSEcCtD
Naproxen—Dermatitis—Temozolomide—melanoma	0.000138	0.000734	CcSEcCtD
Naproxen—Headache—Temozolomide—melanoma	0.000138	0.00073	CcSEcCtD
Naproxen—Hypotension—Docetaxel—melanoma	0.000136	0.000724	CcSEcCtD
Naproxen—Nausea—Carmustine—melanoma	0.000135	0.000716	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Docetaxel—melanoma	0.000133	0.000706	CcSEcCtD
Naproxen—Insomnia—Docetaxel—melanoma	0.000132	0.000701	CcSEcCtD
Naproxen—Paraesthesia—Docetaxel—melanoma	0.000131	0.000696	CcSEcCtD
Naproxen—Nausea—Temozolomide—melanoma	0.00013	0.000692	CcSEcCtD
Naproxen—Dyspnoea—Docetaxel—melanoma	0.00013	0.000691	CcSEcCtD
Naproxen—Indomethacin—ALB—melanoma	0.00013	0.0158	CrCbGaD
Naproxen—Somnolence—Docetaxel—melanoma	0.00013	0.000689	CcSEcCtD
Naproxen—Flurbiprofen—PTGS2—melanoma	0.000129	0.0157	CrCbGaD
Naproxen—Dyspepsia—Docetaxel—melanoma	0.000129	0.000682	CcSEcCtD
Naproxen—Decreased appetite—Docetaxel—melanoma	0.000127	0.000673	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—melanoma	0.000126	0.000669	CcSEcCtD
Naproxen—Fatigue—Docetaxel—melanoma	0.000126	0.000668	CcSEcCtD
Naproxen—Constipation—Docetaxel—melanoma	0.000125	0.000662	CcSEcCtD
Naproxen—Pain—Docetaxel—melanoma	0.000125	0.000662	CcSEcCtD
Naproxen—Indomethacin—ABCB1—melanoma	0.000124	0.0151	CrCbGaD
Naproxen—Feeling abnormal—Docetaxel—melanoma	0.00012	0.000638	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—melanoma	0.000119	0.000633	CcSEcCtD
Naproxen—Ketoprofen—PTGS2—melanoma	0.000117	0.0142	CrCbGaD
Naproxen—Abdominal pain—Docetaxel—melanoma	0.000115	0.000612	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—melanoma	0.000115	0.000612	CcSEcCtD
Naproxen—Flurbiprofen—ALB—melanoma	0.000115	0.014	CrCbGaD
Naproxen—Ibuprofen—PTGS2—melanoma	0.000115	0.014	CrCbGaD
Naproxen—Hypersensitivity—Docetaxel—melanoma	0.000108	0.000571	CcSEcCtD
Naproxen—Asthenia—Docetaxel—melanoma	0.000105	0.000556	CcSEcCtD
Naproxen—Ketoprofen—ALB—melanoma	0.000104	0.0127	CrCbGaD
Naproxen—Pruritus—Docetaxel—melanoma	0.000103	0.000548	CcSEcCtD
Naproxen—Ibuprofen—ALB—melanoma	0.000102	0.0125	CrCbGaD
Naproxen—Diarrhoea—Docetaxel—melanoma	9.99e-05	0.00053	CcSEcCtD
Naproxen—Ibuprofen—ABCB1—melanoma	9.77e-05	0.0119	CrCbGaD
Naproxen—Dizziness—Docetaxel—melanoma	9.66e-05	0.000512	CcSEcCtD
Naproxen—Vomiting—Docetaxel—melanoma	9.29e-05	0.000493	CcSEcCtD
Naproxen—Rash—Docetaxel—melanoma	9.21e-05	0.000488	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—melanoma	9.2e-05	0.000488	CcSEcCtD
Naproxen—Headache—Docetaxel—melanoma	9.15e-05	0.000485	CcSEcCtD
Naproxen—Nausea—Docetaxel—melanoma	8.68e-05	0.00046	CcSEcCtD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	1.25e-05	0.000126	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—melanoma	1.24e-05	0.000124	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.22e-05	0.000123	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPAM—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GNAQ—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CD44—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CD—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.22e-05	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLA2G6—melanoma	1.21e-05	0.000122	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ABCB1—melanoma	1.21e-05	0.000122	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1B—melanoma	1.21e-05	0.000121	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.21e-05	0.000121	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.19e-05	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB4—melanoma	1.19e-05	0.000119	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP3—melanoma	1.18e-05	0.000119	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—melanoma	1.18e-05	0.000119	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN2B—melanoma	1.18e-05	0.000118	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1B1—melanoma	1.17e-05	0.000117	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CD—melanoma	1.16e-05	0.000116	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—melanoma	1.15e-05	0.000116	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CG—melanoma	1.15e-05	0.000115	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—melanoma	1.15e-05	0.000115	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—melanoma	1.14e-05	0.000114	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD86—melanoma	1.14e-05	0.000114	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP17A1—melanoma	1.13e-05	0.000113	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP17A1—melanoma	1.12e-05	0.000113	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—melanoma	1.12e-05	0.000112	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—melanoma	1.12e-05	0.000112	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PRKCA—melanoma	1.12e-05	0.000112	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.11e-05	0.000112	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1A—melanoma	1.11e-05	0.000112	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—melanoma	1.11e-05	0.000112	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—melanoma	1.11e-05	0.000111	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.11e-05	0.000111	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ERCC2—melanoma	1.11e-05	0.000111	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NFKB1—melanoma	1.11e-05	0.000111	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGF1—melanoma	1.1e-05	0.000111	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	1.1e-05	0.00011	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—VCAN—melanoma	1.09e-05	0.000109	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CG—melanoma	1.07e-05	0.000108	CbGpPWpGaD
Naproxen—PTGS2—Disease—PDGFRA—melanoma	1.07e-05	0.000107	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GNA11—melanoma	1.07e-05	0.000107	CbGpPWpGaD
Naproxen—ALB—Metabolism—GNA11—melanoma	1.06e-05	0.000106	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CB—melanoma	1.06e-05	0.000106	CbGpPWpGaD
Naproxen—PTGS2—Disease—PRKCA—melanoma	1.06e-05	0.000106	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERCC2—melanoma	1.05e-05	0.000105	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—FASN—melanoma	1.04e-05	0.000105	CbGpPWpGaD
Naproxen—ALB—Metabolism—FASN—melanoma	1.04e-05	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G6—melanoma	1.04e-05	0.000104	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—melanoma	1.04e-05	0.000104	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—melanoma	1.03e-05	0.000104	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAP2K2—melanoma	1.03e-05	0.000104	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.03e-05	0.000104	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.03e-05	0.000104	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC5A5—melanoma	1.03e-05	0.000103	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	1.03e-05	0.000103	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC5A5—melanoma	1.02e-05	0.000102	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CB—melanoma	1.01e-05	0.000101	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CD—melanoma	1.01e-05	0.000101	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—melanoma	1e-05	0.000101	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—melanoma	1e-05	0.000101	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—melanoma	9.97e-06	0.0001	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	9.96e-06	9.99e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—melanoma	9.94e-06	9.98e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GNAQ—melanoma	9.92e-06	9.95e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CD44—melanoma	9.92e-06	9.95e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—melanoma	9.92e-06	9.95e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—melanoma	9.92e-06	9.95e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GNAQ—melanoma	9.86e-06	9.9e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CD44—melanoma	9.86e-06	9.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—melanoma	9.83e-06	9.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HLA-A—melanoma	9.83e-06	9.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—RAC1—melanoma	9.81e-06	9.84e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—melanoma	9.74e-06	9.78e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.71e-06	9.75e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.66e-06	9.69e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—melanoma	9.63e-06	9.66e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	9.63e-06	9.66e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	9.57e-06	9.6e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1B1—melanoma	9.51e-06	9.54e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—melanoma	9.5e-06	9.53e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1B1—melanoma	9.46e-06	9.49e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CD—melanoma	9.43e-06	9.46e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—melanoma	9.41e-06	9.44e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—melanoma	9.38e-06	9.41e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—VCAN—melanoma	9.32e-06	9.35e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—melanoma	9.31e-06	9.34e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—melanoma	9.24e-06	9.27e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP17A1—melanoma	9.2e-06	9.23e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.17e-06	9.2e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—melanoma	9.15e-06	9.18e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	9.07e-06	9.1e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK1—melanoma	9.04e-06	9.07e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—melanoma	9.04e-06	9.07e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	8.95e-06	8.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PRKCA—melanoma	8.86e-06	8.89e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.82e-06	8.85e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—melanoma	8.8e-06	8.83e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ERCC2—melanoma	8.79e-06	8.82e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—melanoma	8.74e-06	8.77e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—melanoma	8.74e-06	8.77e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—melanoma	8.72e-06	8.75e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GNA11—melanoma	8.69e-06	8.71e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—melanoma	8.56e-06	8.58e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—melanoma	8.54e-06	8.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	8.51e-06	8.54e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—FASN—melanoma	8.5e-06	8.53e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—melanoma	8.47e-06	8.5e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—melanoma	8.44e-06	8.46e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.39e-06	8.42e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A5—melanoma	8.36e-06	8.39e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.35e-06	8.37e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD80—melanoma	8.3e-06	8.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—melanoma	8.29e-06	8.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—melanoma	8.29e-06	8.31e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—melanoma	8.28e-06	8.31e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—melanoma	8.22e-06	8.24e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGF—melanoma	8.19e-06	8.22e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—melanoma	8.18e-06	8.21e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—melanoma	8.14e-06	8.17e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GNAQ—melanoma	8.07e-06	8.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CD44—melanoma	8.07e-06	8.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.91e-06	7.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP17A1—melanoma	7.86e-06	7.89e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—melanoma	7.84e-06	7.87e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.83e-06	7.86e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—melanoma	7.83e-06	7.86e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—melanoma	7.83e-06	7.86e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—melanoma	7.79e-06	7.81e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—melanoma	7.79e-06	7.81e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.75e-06	7.78e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1B1—melanoma	7.74e-06	7.77e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—melanoma	7.68e-06	7.71e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—melanoma	7.66e-06	7.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	7.65e-06	7.68e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—melanoma	7.61e-06	7.63e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—melanoma	7.59e-06	7.61e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—melanoma	7.59e-06	7.61e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK1—melanoma	7.45e-06	7.48e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNA11—melanoma	7.42e-06	7.45e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAP2K1—melanoma	7.33e-06	7.36e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—melanoma	7.28e-06	7.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.28e-06	7.3e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FASN—melanoma	7.26e-06	7.29e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—melanoma	7.26e-06	7.28e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PRKCA—melanoma	7.21e-06	7.23e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PRKCA—melanoma	7.17e-06	7.19e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ERCC2—melanoma	7.15e-06	7.17e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A5—melanoma	7.14e-06	7.17e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ERCC2—melanoma	7.11e-06	7.13e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—melanoma	7.1e-06	7.12e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—melanoma	7.04e-06	7.06e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGF2—melanoma	6.97e-06	7e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—melanoma	6.95e-06	6.97e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—melanoma	6.94e-06	6.96e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CD44—melanoma	6.9e-06	6.92e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNAQ—melanoma	6.9e-06	6.92e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.83e-06	6.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.76e-06	6.78e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—melanoma	6.7e-06	6.72e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—melanoma	6.7e-06	6.72e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.69e-06	6.72e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—melanoma	6.64e-06	6.66e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1B1—melanoma	6.62e-06	6.64e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MDM2—melanoma	6.53e-06	6.55e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—melanoma	6.47e-06	6.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—melanoma	6.43e-06	6.46e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—melanoma	6.41e-06	6.43e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—melanoma	6.37e-06	6.4e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—melanoma	6.35e-06	6.37e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—melanoma	6.34e-06	6.36e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—melanoma	6.26e-06	6.28e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—melanoma	6.16e-06	6.18e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—melanoma	6.1e-06	6.12e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—melanoma	6.02e-06	6.04e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—melanoma	5.98e-06	6e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—melanoma	5.96e-06	5.98e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.92e-06	5.94e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.89e-06	5.91e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PRKCA—melanoma	5.87e-06	5.89e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.84e-06	5.86e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ERCC2—melanoma	5.82e-06	5.84e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—melanoma	5.79e-06	5.81e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—melanoma	5.65e-06	5.67e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—melanoma	5.63e-06	5.65e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—melanoma	5.61e-06	5.63e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—melanoma	5.5e-06	5.52e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—melanoma	5.49e-06	5.5e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—melanoma	5.45e-06	5.47e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—melanoma	5.45e-06	5.47e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—melanoma	5.42e-06	5.44e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—melanoma	5.37e-06	5.39e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—melanoma	5.32e-06	5.33e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—melanoma	5.28e-06	5.3e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—melanoma	5.04e-06	5.05e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PRKCA—melanoma	5.01e-06	5.03e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—melanoma	5.01e-06	5.03e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ERCC2—melanoma	4.97e-06	4.99e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—melanoma	4.96e-06	4.98e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—melanoma	4.94e-06	4.95e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—melanoma	4.91e-06	4.92e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—melanoma	4.9e-06	4.92e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—melanoma	4.89e-06	4.91e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.82e-06	4.84e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—melanoma	4.69e-06	4.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—melanoma	4.6e-06	4.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—melanoma	4.59e-06	4.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—melanoma	4.56e-06	4.57e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK1—melanoma	4.46e-06	4.48e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—melanoma	4.46e-06	4.47e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—melanoma	4.44e-06	4.45e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—melanoma	4.38e-06	4.4e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—melanoma	4.33e-06	4.34e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—melanoma	4.3e-06	4.32e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—melanoma	4.29e-06	4.3e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—melanoma	4.26e-06	4.28e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—melanoma	4.21e-06	4.23e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.12e-06	4.13e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—melanoma	4.09e-06	4.11e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—melanoma	4.08e-06	4.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—melanoma	4.04e-06	4.05e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—melanoma	3.99e-06	4e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—melanoma	3.93e-06	3.94e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—melanoma	3.87e-06	3.88e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—melanoma	3.79e-06	3.8e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—melanoma	3.74e-06	3.75e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—melanoma	3.72e-06	3.73e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—melanoma	3.58e-06	3.59e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—melanoma	3.52e-06	3.53e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—melanoma	3.49e-06	3.5e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—melanoma	3.45e-06	3.46e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—melanoma	3.43e-06	3.44e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—melanoma	3.41e-06	3.42e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—melanoma	3.34e-06	3.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—melanoma	3.24e-06	3.25e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—melanoma	3.16e-06	3.17e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—melanoma	3.04e-06	3.05e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—melanoma	3.01e-06	3.02e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—melanoma	2.98e-06	2.99e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—melanoma	2.65e-06	2.66e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—melanoma	2.64e-06	2.65e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—melanoma	2.62e-06	2.63e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—melanoma	2.6e-06	2.61e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—melanoma	2.15e-06	2.16e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—melanoma	2.15e-06	2.15e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—melanoma	2.14e-06	2.15e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—melanoma	1.83e-06	1.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—melanoma	1.75e-06	1.76e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—melanoma	1.5e-06	1.5e-05	CbGpPWpGaD
